The effect of aldactone-A on intracellular potassium in patients with myasthenia gravis.
D000328:Adult; D001834:Body Water / Q000032:analysis; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000378:metabolism; D011188:Potassium / Q000097:blood / Q000378:metabolism*; D011865:Radioisotope Dilution Technique; D012964:Sodium / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use*; D014882:Water-Electrolyte Balance
D002800:Cholinesterase Inhibitors; D013148:Spironolactone; D012964:Sodium; D011188:Potassium